A phase 2 study of weekly Nab-Paclitaxel followed by FEC (Fluorouracil, Epirubicin, Cyclophosphamide) as primary therapy for operable breast cancer
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000007510
- Lead Sponsor
- ahanishi Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 30
Not provided
1. Cases with prior history of hypersensitivity reaction to the drugs or solvents (e.g. albumin, paclitaxel) used in this protocol. 2. Bilateral breast cancer cases. 3. Cases with inflammatory breast cancer. 4. Male breast cancer cases. 5. Cases with active secondary malignancy (current secondary malignancy or other malignancy within 5 years) . 6. Cases with conditions with the potential to compromise the planned treatment, such as cases with active infection, diarrhea, intestinal paralysis, intestinal obstruction, uncontrolled diabetes, uncontrolled angina and myocardial infarction within 6 months, heart failure, and other serious conditions. 7. Pregnant or breast feeding cases. 8. Cases with pulmonary fibrosis or interstitial pneumonia. 9. Cases with severe myelodepression, renal or liver dysfunction. 10. Cases in which the treating physician deems inappropriate to be entered into this study for other reasons.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method